Developer docs
API playgroundTry for free, no card

Search company profiles

Pharmaxis Group

Full company profile

uuid0009gkq

Namestring
Pharmaxis Group
Legal namestring
Pharmaxis Group
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Pharmaxis Group is a privately held, US-headquartered pharmaceutical distribution and logistics company focused on cross-border access to non-registered, unavailable, discontinued, or short-supply medicines, with an explicit emphasis on orphan and low-prevalence disease treatments. Headquartered in Coral Gables, Florida, with a second US office in Wilmington, North Carolina, the company maintains operations-support presence across Mexico, Colombia, Australia, India, Germany, and the United Kingdom. It serves a horizontal set of B2B and institutional buyers: hospitals and healthcare providers, government health authorities, wholesalers and distributors, medicine importers, specialized pharmacies, and patient support organizations.

The company operates three interconnected services: Named Patient Supply (enabling healthcare professionals to import non-registered medicines on behalf of specific patients), Medicines Shortages Supply (sourcing alternatives when drugs are discontinued or in short supply), and Logistics and Distribution (import/export execution, customs and regulatory adaptation, and cold chain handling). Its operational backbone is a network of GMP-certified international suppliers and CACA/BPA-certified logistics partners, validated cold chain containers maintaining 2–8°C for up to 120 hours, and warehousing positioned in Free Trade Zones. Notably, the company explicitly does not handle registered medicines, positioning itself in the regulatory white space of unlicensed and managed-access pathways.

Commercially, Pharmaxis Group runs a sales-led, direct B2B motion supplemented by a channel-partner model connecting manufacturers to end-users. Revenue is generated on a transaction-fee basis across all three service lines, with pricing undisclosed and quote-based per engagement. Go-to-market is bottom-of-funnel and inquiry-driven, operated through multilingual (English, Spanish, Portuguese) website contact forms for product enquiries, named patient supply, shortage requests, and supplier onboarding. The firm reports 11–50 employees and shows no app, API, or software product surface despite a "SaaS/Marketplace" self-description in firmographic metadata.

Short descriptiontext

US-based pharmaceutical distributor providing cross-border access to non-registered, orphan, and short-supply medicines via named patient supply, shortages sourcing, and cold chain logistics for hospitals, governments, wholesalers, and specialized pharmacies worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCoral Gables, United States
HQ citystring
Coral Gables
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices8 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical distribution services, cold chain logistics, named patient supply, orphan disease medicines, medicines shortage sourcing
Industry2 codes
PRIMARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences
SECONDARYCRAOAHAA
Prescription Pharmaceutical (Rx) Wholesale Distribution
NAICS code1 code
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code1 code
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Pharmaceutical Distribution and Logistics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Named Patient Supply
TypeTransaction Fee
Description

Enabling healthcare professionals to access non-registered medicines on behalf of their patients, serving orphan and low-prevalence disease treatments.

pharmaxisgroup.com
2Medicines Shortages Supply
TypeTransaction Fee
Description

Sourcing globally to healthcare providers, wholesalers, distributors when medicines are discontinued, in short supply, or not available in patient's country.

pharmaxisgroup.com
3Logistics and Distribution
TypeTransaction Fee
Description

Import and export services with specialized expertise for pharmaceutical products including room temperature, cold chain, and controlled medications. Connecting pharmaceutical industry with end-users worldwide.

pharmaxisgroup.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Infrastructure, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Pharmaxis Group is a US-based pharmaceutical distribution and logistics company that supplies non-registered, orphan, and low-prevalence disease medicines to healthcare providers, governments, wholesalers, and patient support organizations worldwide. The company operates through three interconnected service lines: Named Patient Supply, Medicines Shortages Supply, and Logistics and Distribution, leveraging GMP-certified suppliers, cold chain capabilities, and Free Trade Zone warehousing to deliver pharmaceuticals globally.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Pharmaxis Group is a pharmaceutical distribution and logistics company offering three interconnected services: Named Patient Supply, Medicines Shortages Supply, and Logistics and Distribution. The company focuses on closing the gap between patients needing orphan or low-prevalence disease treatments and pharmaceutical manufacturers worldwide. Named Patient Supply allows healthcare professionals to access non-registered medicines on behalf of patients; Medicines Shortages Supply helps source alternatives during shortages; and Logistics and Distribution provides the international shipping, cold chain management, and regulatory compliance infrastructure that underpins both services.

Product and service3 records
1Named Patient Supply
CategoryPharmaceutical Distribution Service
Description

Enables healthcare professionals to access non-registered medicines on behalf of their patients, providing worldwide access to high-quality pharmaceutical products not available in the patient's country. Targets hospitals, clinics, and healthcare providers serving patients with orphan or low-prevalence diseases.

2Medicines Shortages Supply
CategoryPharmaceutical Distribution Service
Description

Helps healthcare providers, governments, and distributors source alternative medicines when facing shortages, connecting patients with needed therapies through a global supplier network. Activated during essential drug shortages affecting patient treatments.

3Logistics and Distribution
CategoryPharmaceutical Logistics and Distribution
Description

Provides specialized import and export services for pharmaceutical products, including cold chain management, controlled medications handling, and coordination with regulatory and customs requirements across multiple countries. Serves as the operational backbone for both Named Patient and Shortages Supply offerings.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1GMP-Certified International Suppliers
Strategic tierCoreTypeTechnology or Integration
Description

Network of international suppliers certified in Good Manufacturing Practices (GMP) for secondary conditioning of drugs with active ingredients and sterile and non-sterile pharmaceutical forms.

pharmaxisgroup.com
Strategic tierCoreTypeTechnology or Integration
Description

Certified strategic partners in Certificate of Storage and Conditioning Capacity (CACA) and Good Storage Practices (BPA) for managing distribution of products with specialized requirements including room temperature, cold chain, and controlled medications.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

European specialty pharma group with named-patient and unlicensed medicine distribution arms — comparable cross-border specialty pharma distribution model.

TypeBroad incumbent
Description

Large global contract pharmaceutical services and distribution provider with cold-chain and clinical-trial supply capabilities — broader portfolio but overlapping specialty distribution and temperature-controlled logistics.

TypeDirect peer
Description

UK-listed global leader in managed access / named patient supply and unlicensed medicine distribution — directly comparable to Pharmaxis's Named Patient Supply and Medicines Shortages Supply services across multiple geographies.

TypeBroad incumbent
Description

One of the largest US pharmaceutical distributors with global specialty distribution and consulting services — broad incumbent with overlapping reach in specialty and orphan pharmaceutical distribution.

5McKesson
TypeBroad incumbent
Description

Global pharmaceutical distributor with a specialty and biotech distribution business serving manufacturers and providers worldwide — broad incumbent whose specialty division is adjacent to Pharmaxis's niche.

TypeDirect peer
Description

UK-based pharmaceutical distributor with a dedicated unlicensed medicines division supplying named-patient and shortage medicines globally — closely overlaps with Pharmaxis's supply and distribution activities.

TypeDirect peer
Description

Specialist in named patient supply and expanded access programs for unlicensed and investigational medicines, serving pharma manufacturers and healthcare providers globally — a close functional analogue to Pharmaxis's core offering.

TypeDirect peer
Description

UK-headquartered unlicensed and investigational medicine supplier serving hospitals and patients worldwide — comparable niche focus on hard-to-source pharmaceuticals through named-patient and managed-access channels.

TypeDirect peer
Description

Amsterdam-based platform enabling pre-approval and managed access to medicines not yet commercially available — directly comparable to Pharmaxis's Named Patient Supply service targeting unmet patient needs.

TypeDirect peer
Description

Finnish specialty pharma company operating a global named patient supply network for anesthesia and orphan therapeutics — directly analogous business model of cross-border unlicensed medicine distribution.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pharmaxis Group

Pharmaceutical Distribution and Logisticspharmaxisgroup.com

US-based pharmaceutical distributor providing cross-border access to non-registered, orphan, and short-supply medicines via named patient supply, shortages sourcing, and cold chain logistics for hospitals, governments, wholesalers, and specialized pharmacies worldwide.

What Pharmaxis Group does

Pharmaxis Group is a privately held, US-headquartered pharmaceutical distribution and logistics company focused on cross-border access to non-registered, unavailable, discontinued, or short-supply medicines, with an explicit emphasis on orphan and low-prevalence disease treatments. Headquartered in Coral Gables, Florida, with a second US office in Wilmington, North Carolina, the company maintains operations-support presence across Mexico, Colombia, Australia, India, Germany, and the United Kingdom. It serves a horizontal set of B2B and institutional buyers: hospitals and healthcare providers, government health authorities, wholesalers and distributors, medicine importers, specialized pharmacies, and patient support organizations.

The company operates three interconnected services: Named Patient Supply (enabling healthcare professionals to import non-registered medicines on behalf of specific patients), Medicines Shortages Supply (sourcing alternatives when drugs are discontinued or in short supply), and Logistics and Distribution (import/export execution, customs and regulatory adaptation, and cold chain handling). Its operational backbone is a network of GMP-certified international suppliers and CACA/BPA-certified logistics partners, validated cold chain containers maintaining 2–8°C for up to 120 hours, and warehousing positioned in Free Trade Zones. Notably, the company explicitly does not handle registered medicines, positioning itself in the regulatory white space of unlicensed and managed-access pathways.

Commercially, Pharmaxis Group runs a sales-led, direct B2B motion supplemented by a channel-partner model connecting manufacturers to end-users. Revenue is generated on a transaction-fee basis across all three service lines, with pricing undisclosed and quote-based per engagement. Go-to-market is bottom-of-funnel and inquiry-driven, operated through multilingual (English, Spanish, Portuguese) website contact forms for product enquiries, named patient supply, shortage requests, and supplier onboarding. The firm reports 11–50 employees and shows no app, API, or software product surface despite a "SaaS/Marketplace" self-description in firmographic metadata.

Pharmaxis Group firmographics

Firmographics
Name
Pharmaxis Group
Legal name
Pharmaxis Group
Website
https://pharmaxisgroup.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
US-based pharmaceutical distributor providing cross-border access to non-registered, orphan, and short-supply medicines via named patient supply, shortages sourcing, and cold chain logistics for hospitals, governments, wholesalers, and specialized pharmacies worldwide.
Ownership category
akta.pro rank

Pharmaxis Group industry classification

Industry
Product category
Pharmaceutical Distribution and Logistics
NAICS
Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences
SECONDARYCRAOAHAA
Prescription Pharmaceutical (Rx) Wholesale Distribution

Keywords

  • Pharmaceutical distribution services
  • Cold chain logistics
  • Named patient supply
  • Orphan disease medicines
  • Medicines shortage sourcing

Where Pharmaxis Group is headquartered

Location

Headquarters

HQ city
Coral Gables
HQ country
United States
HQ region
North America

Offices8 records

Markets served

Pharmaxis Group business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Supply Chain, Operations, Personnel, Infrastructure, Marketing or Sales, Technology or R&D

Revenue model

  1. Named Patient Supply: Enabling healthcare professionals to access non-registered medicines on behalf of their patients, serving orphan and low-prevalence disease treatments.
  2. Medicines Shortages Supply: Sourcing globally to healthcare providers, wholesalers, distributors when medicines are discontinued, in short supply, or not available in patient's country.
  3. Logistics and Distribution: Import and export services with specialized expertise for pharmaceutical products including room temperature, cold chain, and controlled medications. Connecting pharmaceutical industry with end-users worldwide.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels2 records

Pharmaxis Group product offering

Product offering

Core offering

Pharmaxis Group is a US-based pharmaceutical distribution and logistics company that supplies non-registered, orphan, and low-prevalence disease medicines to healthcare providers, governments, wholesalers, and patient support organizations worldwide. The company operates through three interconnected service lines: Named Patient Supply, Medicines Shortages Supply, and Logistics and Distribution, leveraging GMP-certified suppliers, cold chain capabilities, and Free Trade Zone warehousing to deliver pharmaceuticals globally.

Product overview

Pharmaxis Group is a pharmaceutical distribution and logistics company offering three interconnected services: Named Patient Supply, Medicines Shortages Supply, and Logistics and Distribution. The company focuses on closing the gap between patients needing orphan or low-prevalence disease treatments and pharmaceutical manufacturers worldwide. Named Patient Supply allows healthcare professionals to access non-registered medicines on behalf of patients; Medicines Shortages Supply helps source alternatives during shortages; and Logistics and Distribution provides the international shipping, cold chain management, and regulatory compliance infrastructure that underpins both services.

Differentiator

Problem solved

Functional benefit

Products and services

  • Named Patient Supply Enables healthcare professionals to access non-registered medicines on behalf of their patients, providing worldwide access to high-quality pharmaceutical products not available in the patient's country. Targets hospitals, clinics, and healthcare providers serving patients with orphan or low-prevalence diseases.
  • Medicines Shortages Supply Helps healthcare providers, governments, and distributors source alternative medicines when facing shortages, connecting patients with needed therapies through a global supplier network. Activated during essential drug shortages affecting patient treatments.
  • Logistics and Distribution Provides specialized import and export services for pharmaceutical products, including cold chain management, controlled medications handling, and coordination with regulatory and customs requirements across multiple countries. Serves as the operational backbone for both Named Patient and Shortages Supply offerings.

Companies that use Pharmaxis Group

Customer profile

Segments6 records

Ideal customer profiles4 records

Pharmaxis Group technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Pharmaxis Group partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • GMP-Certified International SupplierscoreTechnology or IntegrationNetwork of international suppliers certified in Good Manufacturing Practices (GMP) for secondary conditioning of drugs with active ingredients and sterile and non-sterile pharmaceutical forms.
  • CACA and BPA Certified Strategic PartnerscoreTechnology or IntegrationCertified strategic partners in Certificate of Storage and Conditioning Capacity (CACA) and Good Storage Practices (BPA) for managing distribution of products with specialized requirements including room temperature, cold chain, and controlled medications.

Scale indicators3 records

Recent moves4 records

Expansion highlights4 records

Pharmaxis Group competitors and assessment

Company assessment

Direct peers

  • Eurocept International: European specialty pharma group with named-patient and unlicensed medicine distribution arms — comparable cross-border specialty pharma distribution model.
  • Clinigen Group: UK-listed global leader in managed access / named patient supply and unlicensed medicine distribution — directly comparable to Pharmaxis's Named Patient Supply and Medicines Shortages Supply services across multiple geographies.
  • Durbin PLC: UK-based pharmaceutical distributor with a dedicated unlicensed medicines division supplying named-patient and shortage medicines globally — closely overlaps with Pharmaxis's supply and distribution activities.
  • WEP Clinical: Specialist in named patient supply and expanded access programs for unlicensed and investigational medicines, serving pharma manufacturers and healthcare providers globally — a close functional analogue to Pharmaxis's core offering.
  • BAP Pharma: UK-headquartered unlicensed and investigational medicine supplier serving hospitals and patients worldwide — comparable niche focus on hard-to-source pharmaceuticals through named-patient and managed-access channels.
  • MyTomorrows: Amsterdam-based platform enabling pre-approval and managed access to medicines not yet commercially available — directly comparable to Pharmaxis's Named Patient Supply service targeting unmet patient needs.
  • Primex Pharmaceuticals: Finnish specialty pharma company operating a global named patient supply network for anesthesia and orphan therapeutics — directly analogous business model of cross-border unlicensed medicine distribution.

Broad incumbents

  • Almac Group: Large global contract pharmaceutical services and distribution provider with cold-chain and clinical-trial supply capabilities — broader portfolio but overlapping specialty distribution and temperature-controlled logistics.
  • Cencora (formerly AmerisourceBergen): One of the largest US pharmaceutical distributors with global specialty distribution and consulting services — broad incumbent with overlapping reach in specialty and orphan pharmaceutical distribution.
  • McKesson: Global pharmaceutical distributor with a specialty and biotech distribution business serving manufacturers and providers worldwide — broad incumbent whose specialty division is adjacent to Pharmaxis's niche.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Pharmaxis Group social profiles

Digital presence

Pharmaxis Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pharmaxis Group leadership team

Management profile

Number of profiles

Pharmaxis Group funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pharmaxis Group M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmaxis Group

What does Pharmaxis Group do?

Pharmaxis Group is a US-based pharmaceutical distribution and logistics company that supplies non-registered, orphan, and low-prevalence disease medicines to healthcare providers, governments, wholesalers, and patient support organizations worldwide. The company operates through three interconnected service lines: Named Patient Supply, Medicines Shortages Supply, and Logistics and Distribution, leveraging GMP-certified suppliers, cold chain capabilities, and Free Trade Zone warehousing to deliver pharmaceuticals globally.

Is Pharmaxis Group a public or private company?

Pharmaxis Group is a private company. It is classified as unknown and is currently operating.

When was Pharmaxis Group founded?

Pharmaxis Group was founded in 2023. It employs 11 to 50 people.

Where is Pharmaxis Group based?

Pharmaxis Group is headquartered in Coral Gables, United States, in the North America region.

How does Pharmaxis Group make money?

Three revenue lines are on record. Named Patient Supply is the primary driver. The others are medicines Shortages Supply and logistics and Distribution.

Who are Pharmaxis Group's main competitors?

Direct peers on record are Eurocept International, Clinigen Group, Durbin PLC, WEP Clinical, BAP Pharma, MyTomorrows and Primex Pharmaceuticals. Broad incumbents are Almac Group, Cencora (formerly AmerisourceBergen) and McKesson.

Does Pharmaxis Group have an API?

No public API is recorded for Pharmaxis Group.

What industry is Pharmaxis Group in?

Pharmaxis Group's product category is Pharmaceutical Distribution and Logistics. Its primary akta.pro industry code is HLAGAMAD, Specialty Pharma & Biologics Distribution (GDP-compliant), with a secondary code of CRAOAHAA, Prescription Pharmaceutical (Rx) Wholesale Distribution. Its NAICS code is 424210 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales